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T akotsubo syndrome (TTS) is an acute heart failuresyndrome characterized by left ventricular (LV) dysfunc-
tion and peculiar patterns of wall motion abnormalities
(WMA).1–4 Although this condition typically affects post-
menopausal women and is often preceded by emotional or
physical triggers, recent studies have demonstrated that TTS
is more heterogeneous than previously thought.1,5–9 Several
studies have shown that TTS, which has typically been
considered a benign disease, may represent a serious illness
with mortality rates comparable to acute coronary syndrome
in the acute phase and with a high rate of adverse events at
long-term follow-up.1,10,11
Despite the recent progress in understanding TTS, many
uncertainties remain. Recovery from LV dysfunction is a pivotal
defining characteristic of TTS. However, the pathophysiolog-
ical mechanisms underlying the LV dysfunction are still unclear
and the clinical aspects of recovery have scarcely been
investigated. Previous studies have shown that most patients
with TTS recover from LV dysfunction within 1 to 6 months,
but wide interindividual variation in the duration of the
recovery process has been reported.1,12–14 Moreover, the
clinical implications of recovery time in TTS are also uncertain.
First, it is unclear whether the differences in the duration of
recovery affect outcomes of TTS patients. Second, the specific
clinical parameters that influence or predict the duration of the
LV recovery process are unknown. Finally, patients with higher
risk of late resolution of WMA cannot currently be identified
during the acute phase. This last issue might be of particular
importance because this patient population may require longer
monitoring and supportive therapy to improve outcomes.
In this analysis, we aimed to assess the clinical features
of TTS patients without early resolution of WMA and to
compare their outcomes to those of patients with early
resolution of WMA. Furthermore, clinical parameters
associated with the absence of early recovery were
investigated.
Methods
Study Population
Data were collected from the InterTAK Registry (Interna-
tional Takotsubo Registry, www.takotsubo-registry.com),15
which is a multicenter, prospective, and retrospective
observational registry established at the University Hospital
Zurich in 2011. The authors declare that all supporting data
are available within the article. The study design, methods,
and objectives were reported recently in a previous study.1
TTS was defined based on InterTAK Diagnostic Criteria.3
Medical records were reviewed by investigators at the
University Hospital Zurich. Uncertain cases were reviewed
by core team members at the University Hospital Zurich,
and the decision for inclusion or exclusion was reached by
consensus. Follow-up information was obtained from med-
ical records, telephone interviews, or clinical visits. The
study protocol was reviewed by the respective local ethics
committee or investigational review board at each collabo-
ration site. Given the partly retrospective nature of the
study, ethics committees of most study centers waived the
need for informed consent. At centers for which the ethics
committees or investigational review boards required
informed consent or from which patients were included
prospectively, formal written consent was obtained from
patients or surrogates.
Recovery Analysis
Recovery was defined as complete resolution of WMA in
follow-up echocardiography or cardiac magnetic resonance
imaging compared with the initial echocardiogram or ven-
triculogram. Patients were divided into 2 groups based on the
presence or absence of WMA recovery within 10 days after
TTS onset. Accordingly, patients who demonstrated recovery
within 10 days of the index event were assigned to the early
recovery group, whereas patients with persistent WMA after
10 days were allocated to the group without early recovery
(Figure 1). These groups were compared to explore the
differences in clinical profiles and outcomes. Patients who
could not be categorized in one of the groups (eg, patients
with documentation of resolution of WMA after several weeks
without recovery information at previous time points) were
not included in the analysis.
Clinical Perspective
What Is New?
• Left ventricular recovery in takotsubo syndrome varies from
days to weeks.
• Patients with early left ventricular recovery have a different
clinical phenotype and more favorable outcomes compared
with patients without early recovery.
• Factors associated with absence of early recovery were
male sex, reduced left ventricular ejection fraction, and
acute neurologic events.
What Are the Clinical Implications?
• The findings of this study highlight that takotsubo syndrome
patients without early recovery have worse outcomes
compared with patients with early recovery and thus should
be monitored closely.
• Prospective studies are needed to unravel the pathophys-
iological mechanisms of left ventricular recovery in patients
with takotsubo syndrome.
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Study Outcomes
Data regarding in-hospital complications (cardiogenic shock,
death, ventricular thrombus) and their management (invasive or
noninvasive ventilation, catecholamine administration) were
recorded. The main outcome measure of this analysis was 1-
year mortality. Patients whose follow-up was shorter than 10
days or who died during the first 10 days after TTS event were
excluded from the analysis. Consequently, the qualifying events
for outcome analysis were recorded from the 11th day after
admission. Factors associated with the absence of early
recovery in TTS patients were also investigated.
Statistical Analyses
Continuous variables are reported as meanSD or median
with interquartile range, whereas categorical variables are
presented as frequency with percentage. Continuous
variables were compared using the Mann–Whitney U
test, whereas the Pearson v2 test (or Fisher exact test,
as appropriate) was used for the comparison of categori-
cal variables. Survival estimates were assessed using
Kaplan–Meier curves, and group differences were evaluated
with the log-rank test. Multivariable logistic regression was
used to identify the parameters associated with the absence
of early recovery in TTS patients. Covariates with P<0.05 at
baseline comparison between the groups (with versus without
early recovery) were included in the multivariable model; a
multiple regression imputation analysis was then performed
to account for missing values. The cut-off for statistical
significance was set at a 2-sided P value <0.05. Odds ratios
are reported with the respective 95% CIs. Analyses were
computed with SPSS statistical software, version 23.0 (IBM
Corp). Figures were created with Prism 7 software (Graph-
Pad).
Results
Patient Characteristics
Of 406 patients, 191 (47%) were assigned to the early recovery
group (Figure 1). In the early recovery group, median time to
WMA resolution was 5 days (interquartile range: 3–7 days).
In the group without early recovery, follow-up imaging
Figure 1. Study flowchart. +WMA indicates persistent wall motion abnormalities; WMA, complete
resolution of wall motion abnormalities.
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assessment was performed at a median of 30 days (interquar-
tile range: 14–57 days). The baseline features of the 2 study
groups are shown in Table. Patients without early resolution of
WMA were more often male (12.6% versus 5.2%, P=0.011) and
were more likely to have physical triggers (46.5% versus 35.1%,
P=0.020) compared with patients with early resolution of
WMA. Patients without early resolution of WMA had higher
prevalence of comorbidities, particularly acute neurologic
disorders, such as intracranial bleeding, stroke or seizure
(9.6% versus 1.7%, P=0.001), and malignancies (22.1% versus
12.2%, P=0.010). TTS patients without early resolution of WMA
presented with typical TTS more frequently (76.3% versus
67.0%, P=0.040) and had lower LV ejection fraction (LVEF) on
admission (37.310.7% versus 43.711.9%, P<0.001). More-
over, patients without early resolution of WMA presented with
higher values of troponin, CRP (C-reactive protein), and white
blood cell counts on admission.
Outcomes
Patients without early resolution of WMA required invasive and
noninvasive ventilation more frequently compared with
patients with early resolution of WMA (26.0% versus 14.7%,
P=0.005).Moreover, a trend toward a higher rate of cardiogenic
shock was observed in TTS patients without early resolution of
WMA (15.0% versus 8.9%, P=0.06). Interestingly, a significantly
higher prevalence of ventricular thrombus was shown in TTS
patients without early resolution of WMA (2.9% versus 0.0%,
P=0.030). In addition, inotropic agents were more frequently
used in patients in the group without early recovery, although
the difference was not significant (16.7% versus 11.0%,
P=0.10). Patients without early resolution of WMA had a
significantly higher mortality rate at 1-year compared with
patients with early recovery of WMA (7.4% versus 1.3%,
P=0.003; Figure 2).
Factors Associated With Absence of Early
Recovery
Multivariable logistic regression analysis was conducted,
including covariates with significant differences (P<0.05) at
baseline between patients with and without early recovery
(Figure 3). We identified male sex, LVEF <45%, and a
composite of acute neurologic events as factors associated
with the absence of early recovery. The results remained
similar after excluding the composite of acute neurologic
disorders from the multivariable model (Figure S1).
Discussion
To our knowledge, this study is the largest investigating the
predictors and prognostic impact of absence of early recovery
in TTS. The study had 3 main findings: (1) patients with longer
recovery time for WMA were more frequently male, had a
higher prevalence of physical triggers initiating TTS, presented
more commonly with typical TTS (apical ballooning), and
presented with lower LVEF and higher troponin and inflam-
matory marker levels on admission; (2) male sex, LVEF <45%,
and concomitant acute neurologic events were associated
with the absence of early recovery in TTS; and (3) delayed
resolution of WMA was associated with higher mortality at
1-year.
On multivariable analysis, male sex, depressed LVEF, and
acute neurologic comorbidities were identified as risk
factors associated with the absence of early recovery.
These results are clinically important because patients with
these characteristics should be monitored closely after
hospitalization, given the higher risk of potential clinical
complications. A previous study by Shiomura et al reported
brain natriuretic peptide levels, body mass index, and
nonuse of calcium channel blockers as independent
predictors for delayed LV recovery. However, the difference
in their findings may be due to the small size of that study
(n=60).16
Rates of cardiogenic shock and invasive or noninvasive
ventilation were higher in the group without early recovery. In
addition, patients with longer WMA recovery duration
appeared to be more susceptible to ventricular thrombus
formation, most likely because of the extent of myocardial
involvement and longer impairment of LV function. Neverthe-
less, a complicated acute course of the disease might
adversely impact the recovery rate. The fact that those with
prolonged recovery presented with higher troponin levels and
lower LVEF supports this interpretation. It may just take more
time to recover from a severely depressed LVEF than from a
mild impairment of pump function.
Patients without early resolution of WMA had significantly
elevated inflammatory markers, but these findings were not
significant on multivariable analysis. Higher levels of inflamma-
tory markers may have affected the outcome; however,
inflammatory response could be due to the preexisting
comorbidities in these patients. Indeed, TTS patients with
longer recovery from WMA more commonly experienced acute
neurologic conditions, which are known to be associated with
elevated CRP levels. Similarly, it is known that neurologic
disorders may lead to profound cardiac damage with patho-
logical changes including contraction band necrosis, found in
autopsied patients with sudden unexpected death in epilepsy
as well as in TTS patients.17,18 In this regard, TTS patients with
acute neurologic comorbidities might have more severe
“neurocardiac damage” with longer LV recovery times.
Schwarz et al recently reported persistent WMA at 4-
month follow-up despite overall normalization of LVEF in some
TTS patients.19 The researchers noted subtle cardiac
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Table. Patient Characteristics
Characteristic TTS With Early Recovery (n=191) TTS Without Early Recovery (n=215) P Value
Demographics
Female sex 181/191 (94.8) 188/369 (87.4) 0.011
Age, y 64.213.0 (n=191) 66.112.8 (n=215) 0.13
Symptoms and triggers
Chest pain 131/175 (74.9) 127/192 (66.1) 0.07
Dyspnea 90/175 (51.4) 98/195 (50.3) 0.82
Physical trigger 67/191 (35.1) 100/215 (46.5) 0.020
Emotional trigger 60/191 (31.4) 62/215 (28.8) 0.57
Cardiac biomarkers
Troponin on admission—factor increase in ULN* 5.96 (1.89–13.15); n=156 7.29 (2.00–23.54); n=168 0.040
Creatine kinase on admission—factor increase in ULN 0.83 (0.52–1.20); n=148 0.84 (0.48–1.43); n=141 0.92
BNP on admission—factor increase in ULN† 4.97 (2.44–12.80); n=57 9.87 (2.74–27.07); n=65 0.12
Inflammatory markers
CRP on admission, mg/L 3.35 (1.03–8.98); n=132 5.10 (2.30–18.40); n=125 0.005
WBC on admission, 103/lL 9.00 (7.11–11.65); n=169 10.40 (7.67–12.65); n=185 0.010
ECG on admission
Sinus rhythm 161/169 (95.3) 172/185 (93.0) 0.36
Atrial fibrillation 7/169 (4.1) 12/185 (6.5) 0.33
AV block (I, II, or III) 5/169 (3.0) 17/185 (9.2) 0.020
ST-segment elevation 63/169 (37.3) 72/185 (38.9) 0.75
ST-segment depression 9/169 (5.3) 14/185 (7.6) 0.39
T-wave inversion 72/169 (42.6) 79/185 (42.7) 0.99
QTc, ms 457.446.8 (n=140) 459.843.7 (n=151) 0.64
Imaging and hemodynamic findings
Apical type 128/191 (67.0) 164/215 (76.3) 0.040
LV ejection fraction, %‡ 43.711.9 (n=169) 37.310.7 (n=191) <0.001
LV end-diastolic pressure, mm Hg 21.38.9 (n=114) 22.27.6 (n=114) 0.40
Heart rate, beats/min 87.722.5 (n=151) 91.323.3 (n=162) 0.17
Systolic blood pressure, mm Hg 131.333.3 (n=157) 131.830.0 (n=166) 0.67
Cardiovascular risk factors/history
Hypertension 124/188 (66.0) 133/210 (63.3) 0.56
Diabetes mellitus 29/186 (15.6) 29/210 (13.8) 0.62
Hypercholesterolemia 58/183 (31.7) 82/207 (39.6) 0.10
Coexisting medical condition
Acute intracranial bleeding, stroke/TIA, seizure 3/173 (1.7) 20/208 (9.6) 0.001
Past or chronic neurologic disorders 24/172 (14.0) 46/205 (22.4) 0.035
Acute psychiatric disorders 18/173 (10.4) 19/208 (9.1) 0.68
Past or chronic psychiatric disorders 47/172 (27.3) 53/205 (25.9) 0.75
Cancer (total) 22/181 (12.2) 44/199 (22.1) 0.010
Medication on admission
ACE inhibitor or ARB 52/156 (33.3) 60/163 (36.8) 0.52
Beta-blocker 59/156 (37.8) 47/164 (28.7) 0.08
Continued
DOI: 10.1161/JAHA.118.011194 Journal of the American Heart Association 5
Recovery in Takotsubo Syndrome Jurisic et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on November 4, 2019
deformations and impaired contraction as assessed by LV
twist and strain analysis. Moreover, a previous study by Scally
et al reported impaired cardiac energetic status and the
development of a heart failure phenotype on long-term follow-
up in some TTS patients.20 These results suggest the
occurrence of prolonged impairment of cardiac function
despite visual assessment suggestive of recovery of WMA
and LVEF improvement. This surprising persistence of cardiac
functional impairments in TTS should be evaluated further; the
issue of “incomplete recovery” is a relatively new concept,
and its mechanisms and clinical implications are
unknown.20,21
We sought to provide parameters that are relatively easy to
obtain in daily clinical practice to detect TTS patients with
potentially longer recovery times for WMA. Our results
suggest the importance of clinical vigilance in TTS patients,
particularly those with prolonged resolution of WMA. Future
studies evaluating therapeutic strategies are needed to
Table. Continued
Characteristic TTS With Early Recovery (n=191) TTS Without Early Recovery (n=215) P Value
Calcium-channel antagonist 9/156 (5.8) 8/163 (4.9) 0.73
Statin 23/156 (14.7) 25/163 (15.3) 0.88
Aspirin 50/156 (32.1) 49/163 (30.1) 0.70
In-hospital complications and management
Cardiogenic shock 17/191 (8.9) 32/214 (15.0) 0.06
Death 5/191 (2.6) 7/215 (3.3) 0.71
Catecholamine use 21/191 (11.0) 36/215 (16.7) 0.10
Ventricular thrombus 0/189 (0.0) 6/210 (2.9) 0.030
Invasive or noninvasive ventilation 28/191 (14.7) 56/215 (26.0) 0.005
Values are mean  SD, no./total n (%), or median (interquartile range). ACE indicates angiotensin-converting-enzyme; ARB, angiotensin-receptor blocker; AV block, atrioventricular block;
BNP, brain natriuretic peptide; CRP, C-reactive protein; IQR, interquartile range; LV, left ventricular; QTc, QT interval corrected for heart rate; TIA, transient ischemic attack; TTS, takotsubo
syndrome; ULN, upper limit of the normal range; WBC white blood cell count.
*Including ULNs for troponin T, high-sensitivity troponin T, and troponin I.
†Including ULNs for brain natiuretic peptide and the N-terminal of prohormone brain natiuretic peptide.
‡LV ejection fraction (%): information from catheterization or echocardiography, if both available: catheterization.
Figure 2. Long-term outcome in takotsubo syndrome (TTS) patients with and without early recovery.
Kaplan–Meier survival analysis demonstrated significant differences in 1-year mortality in TTS patients
without early recovery than in those with early recovery (P=0.003).
DOI: 10.1161/JAHA.118.011194 Journal of the American Heart Association 6
Recovery in Takotsubo Syndrome Jurisic et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on November 4, 2019
accelerate LV recovery and to improve long-term prognosis in
TTS patients.
Study Limitations
This study is partly retrospective in nature and is based on an
international multicenter registry. Moreover, the dichotomous
classification of those with and without early recovery may
influence our results because a priori imaging time points
were not selected. The vast majority of imaging studies were
performed by echocardiography; cardiac magnetic resonance
imaging was not performed in all patients because data went
back to 1998, when cardiac magnetic resonance imaging was
not broadly and systematically available.22 The multivariable
analysis did not demonstrate an association between physical
triggers and the absence of early recovery, likely because of
the sample size of the study. Multivariable logistic regression
analysis was used to investigate the covariates associated
with the absence of early recovery, given the retrospective
limitation of assessing the exact time to recovery. Further-
more, multivariable assessment of survival was not performed
because of the limited number of events at follow-up, which
prevented the establishment of an accurate and reliable
model.
Conclusions
This study offers new insights into the clinical impact of LV
recovery time in TTS patients. Patients without early LV
recovery have higher prevalence of in-hospital complications
and higher mortality and should be monitored closely. Further
prospective studies are needed to uncover the actual
mechanism underlying LV recovery in TTS.
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Figure S1. Multivariate logistic regression 
 
 
 
Multivariate logistic regression revealed similar results both before and after excluding 
the composite of acute neurologic disorders.  
Error bars represent 95% confidence interval. 
Black rhombi indicate statistical significance; grey rhombi not statistically significant. 
C.I., confidence interval; LVEF, left ventricular ejection fraction; OR, odds ratio; ULN, 
upper limit of the normal range; WBC, white blood cell count. 
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